Ciro Mercurio

List of Publications by Year
in descending order

61 papers	2,839 citations	147566 31 h-index	174990 52 g-index
63 all docs	63 docs citations	63 times ranked	4896 citing authors

#	Article	IF	Citations
1	Novel Pyridineâ€Based Hydroxamates and 2â€²â€Aminoanilides as Histone Deacetylase Inhibitors: Biochemical Profile and Anticancer Activity. ChemMedChem, 2021, 16, 989-999.	1.6	8
2	LSD1-directed therapy affects glioblastoma tumorigenicity by deregulating the protective ATF4-dependent integrated stress response. Science Translational Medicine, 2021, 13, eabf7036.	5.8	18
3	Discovery of Reversible Inhibitors of KDM1A Efficacious in Acute Myeloid Leukemia Models. ACS Medicinal Chemistry Letters, 2020, 11, 754-759.	1.3	21
4	TranylcyprimineâBased LSD1 Inhibitors: Structureâ€Activity Relationships, Antiproliferative Effects in Leukemia, and Gene Target Modulation. ChemMedChem, 2020, 15, 643-658.	1.6	18
5	Targeting the scaffolding role of LSD1 (KDM1A) poises acute myeloid leukemia cells for retinoic acidâ€“induced differentiation. Science Advances, 2020, 6, eaax2746.	4.7	56
6	New 6- and 7-heterocyclyl-1H-indole derivatives as potent tubulin assembly and cancer cell growth inhibitors. European Journal of Medicinal Chemistry, 2018, 152, 283-297.	2.6	30
7	New targets to modulate the DNA damage response. Future Medicinal Chemistry, 2018, 10, 2377-2380.	1.1	0
8	Thieno[3,2-b]pyrrole-5-carboxamides as New Reversible Inhibitors of Histone Lysine Demethylase KDM1A/LSD1. Part 1: High-Throughput Screening and Preliminary Exploration. Journal of Medicinal Chemistry, 2017, 60, 1673-1692.	2.9	59
9	Thieno[3,2-b]pyrrole-5-carboxamides as New Reversible Inhibitors of Histone Lysine Demethylase KDM1A/LSD1. Part 2: Structure-Based Drug Design and Structureâ€“Activity Relationship. Journal of Medicinal Chemistry, 2017, 60, 1693-1715.	2.9	60
10	3-Aroyl-1,4-diarylpyrroles Inhibit Chronic Myeloid Leukemia Cell Growth through an Interaction with Tubulin. ACS Medicinal Chemistry Letters, 2017, 8, 521-526.	1.3	8
11	Novel potent inhibitors of the histone demethylase KDM1A (LSD1), orally active in a murine promyelocitic leukemia model. Future Medicinal Chemistry, 2017, 9, 1161-1174.	1.1	4
12	Compounds and methods for inhibiting histone demethylases: a patent evaluation of US20160102096A1. Expert Opinion on Therapeutic Patents, 2016, 26, 1367-1370.	2.4	3
13	Discovery of a Novel Inhibitor of Histone Lysine-Specific Demethylase 1A (KDM1A/LSD1) as Orally Active Antitumor Agent. Journal of Medicinal Chemistry, 2016, 59, 1501-1517.	2.9	70
14	Synthesis, biological characterization and molecular modeling insights of spirochromanes as potent HDAC inhibitors. European Journal of Medicinal Chemistry, 2016, 108, 53-67.	2.6	26
15	Dual modulation of MCL-1 and mTOR determines the response to sunitinib. Journal of Clinical Investigation, 2016, 127, 153-168.	3.9	49
16	Pure enantiomers of benzoylamino-tranylcypromine: LSD1 inhibition, gene modulation in human leukemia cells and effects on clonogenic potential of murine promyelocytic blasts. European Journal of Medicinal Chemistry, 2015, 94, 163-174.	2.6	28
17	Further insights into the SAR of Î±-substituted cyclopropylamine derivatives as inhibitors of histone demethylase KDM1A. European Journal of Medicinal Chemistry, 2015, 92, 377-386.	2.6	30
18	Pyrrole- and indole-containing tranylcypromine derivatives as novel lysine-specific demethylase 1 inhibitors active on cancer cells. MedChemComm, 2015, 6, 665-670.	3.5	24

#	Article	IF	Citations
19	New Indole Tubulin Assembly Inhibitors Cause Stable Arrest of Mitotic Progression, Enhanced Stimulation of Natural Killer Cell Cytotoxic Activity, and Repression of Hedgehog-Dependent Cancer. Journal of Medicinal Chemistry, 2015, 58, 5789-5807.	2.9	51
20	Pure Diastereomers of a Tranylcypromine-Based LSD1 Inhibitor: Enzyme Selectivity and In-Cell Studies. ACS Medicinal Chemistry Letters, 2015, 6, 173-177.	1.3	16
21	Inhibition of the Histone Demethylase LSD1 Combined with Caloric Restriction or IGF1/Insulin Inhibition Leads to Durable Responses in a Preclinical Model of Acute Myeloid Leukemia. Blood, 2015, 126, 459-459.	0.6	0
22	Synthesis, biological activity and mechanistic insights of 1-substituted cyclopropylamine derivatives: A novel class of irreversible inhibitors of histone demethylase KDM1A. European Journal of Medicinal Chemistry, 2014, 86, 352-363.	2.6	50
23	Chiral Resolution and Pharmacological Characterization of the Enantiomers of the Hsp90 Inhibitor 2â€Aminoâ€7â€[4â€fluoroâ€2â€(3â€pyridyl)phenyl]â€4â€methylâ€7,8â€dihydroâ€6Hâ€quinazolinâ€5â€one Oxime. ChemMed 2014, 9, 1574-1585.		6
24	Beclin 1 restrains tumorigenesis through Mcl-1 destabilization in an autophagy-independent reciprocal manner. Nature Communications, 2014, 5, 5637.	5.8	65
25	Towards Selective Inhibition of Histone Deacetylase Isoforms: What Has Been Achieved, Where We Are and What Will Be Next. ChemMedChem, 2014, 9, 523-536.	1.6	83
26	New Pyrrole Derivatives with Potent Tubulin Polymerization Inhibiting Activity As Anticancer Agents Including Hedgehog-Dependent Cancer. Journal of Medicinal Chemistry, 2014, 57, 6531-6552.	2.9	80
27	tertâ€Butylcarbamateâ€Containing Histone Deacetylase Inhibitors: Apoptosis Induction, Cytodifferentiation, and Antiproliferative Activities in Cancer Cells. ChemMedChem, 2013, 8, 800-811.	1.6	16
28	Toward Highly Potent Cancer Agents by Modulating the C-2 Group of the Arylthioindole Class of Tubulin Polymerization Inhibitors. Journal of Medicinal Chemistry, 2013, 56, 123-149.	2.9	107
29	Synthesis and biological characterization of spiro[2H-(1,3)-benzoxazine-2,4â€²-piperidine] based histone deacetylase inhibitors. European Journal of Medicinal Chemistry, 2013, 64, 273-284.	2.6	14
30	Design, synthesis and preliminary evaluation of a series of histone deacetylase inhibitors carrying a benzodiazepine ring. European Journal of Medicinal Chemistry, 2013, 66, 56-68.	2.6	16
31	Antiâ€tumour efficacy on glioma models of <scp>PHA</scp>â€848125, a multiâ€kinase inhibitor able to cross the bloodâ€“brain barrier. British Journal of Pharmacology, 2013, 169, 156-166.	2.7	18
32	Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL. Leukemia, 2012, 26, 1630-1637.	3.3	48
33	Alterations of Histone Modifications in Cancer. , 2012, , 53-87.		5
34	Spiro[chromaneâ€2,4â€²â€piperidine]â€Based Histone Deacetylase Inhibitors with Improved inâ€…vivo Activity. ChemMedChem, 2012, 7, 709-721.	1.6	11
35	Design and Synthesis of 2-Heterocyclyl-3-arylthio-1H-indoles as Potent Tubulin Polymerization and Cell Growth Inhibitors with Improved Metabolic Stability. Journal of Medicinal Chemistry, 2011, 54, 8394-8406.	2.9	70
36	Discovery, Synthesis, and Pharmacological Evaluation of Spiropiperidine Hydroxamic Acid Based Derivatives as Structurally Novel Histone Deacetylase (HDAC) Inhibitors. Journal of Medicinal Chemistry, 2011, 54, 3051-3064.	2.9	50

#	Article	IF	Citations
37	Interplay between oncogene-induced DNA damage response and heterochromatin in senescence and cancer. Nature Cell Biology, 2011, 13, 292-302.	4.6	294
38	Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing. Bioorganic and Medicinal Chemistry, 2010, 18, 1844-1853.	1.4	58
39	Synthesis and Biological Characterization of Amidopropenyl Hydroxamates as HDAC Inhibitors. ChemMedChem, 2010, 5, 1359-1372.	1.6	13
40	Design and synthesis of novel isoxazole-based HDAC inhibitors. European Journal of Medicinal Chemistry, 2010, 45, 4331-4338.	2.6	30
41	Dual Targeting of CDK and Tropomyosin Receptor Kinase Families by the Oral Inhibitor PHA-848125, an Agent with Broad-Spectrum Antitumor Efficacy. Molecular Cancer Therapeutics, 2010, 9, 2243-2254.	1.9	48
42	Transcriptional Analysis of an E2F Gene Signature as a Biomarker of Activity of the Cyclin-Dependent Kinase Inhibitor PHA-793887 in Tumor and Skin Biopsies from a Phase I Clinical Study. Molecular Cancer Therapeutics, 2010, 9, 1265-1273.	1.9	15
43	Pathology tissueâ€“chromatin immunoprecipitation, coupled with high-throughput sequencing, allows the epigenetic profiling of patient samples. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 21535-21540.	3.3	63
44	Histone deacetylases and epigenetic therapies of hematological malignancies. Pharmacological Research, 2010, 62, 18-34.	3.1	121
45	Synthesis and Biological Evaluation of N-Hydroxyphenylacrylamides and N-Hydroxypyridin-2-ylacrylamides as Novel Histone Deacetylase Inhibitors. Journal of Medicinal Chemistry, 2010, 53, 822-839.	2.9	32
46	Identification of Potent Pyrazolo[4,3-h]quinazoline-3-carboxamides as Multi-Cyclin-Dependent Kinase Inhibitors. Journal of Medicinal Chemistry, 2010, 53, 2171-2187.	2.9	36
47	Fragmentâ€based Identification of Hsp90 Inhibitors. ChemMedChem, 2009, 4, 963-966.	1.6	49
48	Identification of N,1,4,4-Tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carbo (PHA-848125), a Potent, Orally Available Cyclin Dependent Kinase Inhibitor. Journal of Medicinal Chemistry, 2009, 52, 5152-5163.	2.9	111
49	Triazole-Modified Histone Deacetylase Inhibitors As a Rapid Route to Drug Discovery. ACS Combinatorial Science, 2008, 10, 624-627.	3.3	22
50	6-Substituted Pyrrolo[3,4-c]pyrazoles: An Improved Class of CDK2 Inhibitors. ChemMedChem, 2007, 2, 841-852.	1.6	21
51	Cross platform microarray analysis for robust identification of differentially expressed genes. BMC Bioinformatics, 2007, 8, S5.	1.2	55
52	3-Amino-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: A new class of CDK2 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 1084-1090.	1.0	56
53	Cyclin-Dependent Kinase 2 Functions in Normal DNA Repair and Is a Therapeutic Target in BRCA1-Deficient Cancers. Cancer Research, 2006, 66, 8219-8226.	0.4	114
54	3-Aminopyrazole Inhibitors of CDK2/Cyclin A as Antitumor Agents. 2. Lead Optimization. Journal of Medicinal Chemistry, 2005, 48, 2944-2956.	2.9	98

#	Article	IF	Citations
55	The Antidiabetic Agent Sodium Tungstate Activates Glycogen Synthesis through an Insulin Receptor-independent Pathway. Journal of Biological Chemistry, 2003, 278, 42785-42794.	1.6	39
56	Drf1, a novel regulatory subunit for human Cdc7 kinase. EMBO Journal, 2002, 21, 3171-3181.	3.5	73
57	Human Cdc25 A inactivation in response to S phase inhibition and its role in preventing premature mitosis. EMBO Reports, 2000, 1, 71-79.	2.0	190
58	Down-Regulation of Protein Kinase CKII Activity by Sodium Butyrate. Biochemical and Biophysical Research Communications, 1997, 233, 673-677.	1.0	19
59	Purification and Characterization of Recombinant Human 5â€²-Methylthioadenosine Phosphorylase: Definite Identification of Coding cDNA. Biochemical and Biophysical Research Communications, 1996, 223, 514-519.	1.0	10
60	Biochemical Characterization of p16 - and p18-containing Complexes in Human Cell Lines. Journal of Biological Chemistry, 1996, 271, 15942-15949.	1.6	51
61	p16INK4 gene deletions in childhood acute lymphoblastic leukemias. Leukemia Research, 1995, 19, 883-885.	0.4	3